(Q34434818)

2 August 2017

1 reference

title

Progress toward an elusive goal: current status of cytomegalovirus vaccines (English)

1 reference

2 August 2017

0 references

1

Mark R Schleiss

1 reference

2 August 2017

Thomas C Heineman

2

1 reference

2 August 2017

1 June 2005

1 reference

Expert Review of Vaccines

2 August 2017

1 reference

2 August 2017

4

1 reference

2 August 2017

381-406

1 reference

2 August 2017

3

1 reference

Genetic content of wild-type human cytomegalovirus.

2 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Human cytomegalovirus virion proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Antibodies to Recombinant-Derived Glycoprotein B after Natural Human Cytomegalovirus Infection Correlate with Neutralizing Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Analysis of human antibody responses to human cytomegalovirus envelope glycoproteins found in two families of disulfide linked glycoprotein complexes designated gC-I and gC-II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Complex formation by glycoproteins M and N of human cytomegalovirus: structural and functional aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Identification of a conserved HLA-A2-restricted decapeptide from the IE1 protein (pUL123) of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

The role of cytomegalovirus-encoded homologs of G protein-coupled receptors and chemokines in manipulation of and evasion from the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Structural and functional aspects of the Ly49 natural killer cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Viral modulation of NK cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Newborn hearing screening: will children with hearing loss caused by congenital cytomegalovirus infection be missed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Overview of congenitally and perinatally acquired cytomegalovirus infections: recent advances in antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

The outcome of congenital cytomegalovirus infection in relation to maternal antibody status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Maternal immunity and prevention of congenital cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cytomegalovirus infection of extremely low-birth weight infants via breast milk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Postnatally acquired cytomegalovirus infection via breast milk: effects on hearing and development in preterm infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

The molecular epidemiology of cytomegalovirus transmission among children attending a day care center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Prevention of child-to-mother transmission of cytomegalovirus among pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Encouraging prospects for immunisation against primary cytomegalovirus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cytomegalovirus and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Asymptomatic primary cytomegalovirus infection: virologic and immunologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cytomegalovirus infection in sex partners: evidence for sexual transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cytomegalovirus Infection in Sexually Active Adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Replication-defective mutants of mouse cytomegalovirus protect against wild-type virus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Expression of the murine cytomegalovirus glycoprotein H by recombinant vaccinia virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Intranasal immunization with a replication-deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

High-frequency interferon-gamma-secreting splenocytes specific for murine cytomegalovirus immediate-early-1 (IE-1) peptide 168YPHFMPTNL176 are insufficient to provide complete protection from viral challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Recent advances in herpesvirus genetics using bacterial artificial chromosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Vaccination of mice with bacteria carrying a cloned herpesvirus genome reconstituted in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Brain and visceral involvement during congenital cytomegalovirus infection of guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Congenital cytomegalovirus labyrinthitis and sensorineural hearing loss in guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Vaccination for the Prevention of Maternal and Fetal Infection with Guinea Pig Cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Identification of an abundant disulfide-linked complex of glycoproteins in the envelope of guinea pig cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Immunisation trials with live attenuated cytomegalovirus TOWNE 125

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Safety and immunogenicity of the Towne strain cytomegalovirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

A review of genetic differences between limited and extensively passaged human cytomegalovirus strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Vaccination against cytomegalovirus, the changeling demon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Structural and immunological characterization of human cytomegalovirus gp55-116 (gB) expressed in insect cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

DNA vaccines against cytomegalovirus: current progress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Optimization of DNA immunization against human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

DNA and low titer, helper-free, recombinant AAV prime-boost vaccination for cytomegalovirus induces an immune response to CMV-pp65 and CMV-IE1 in transgenic HLA A*0201 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Poxviruses as vaccine vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Progress made towards the development of a CMV peptide vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Induction of CTL response by a minimal epitope vaccine in HLA A*0201/DR1 transgenic mice: dependence on HLA class II restricted T(H) response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Protein delivery by subviral particles of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Severe herpesvirus infections in an adolescent without natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.4.3.381

21 January 2018

Identifiers

DOI

10.1586/14760584.4.3.381

1 reference

2 August 2017

1 reference

PubMed ID

16026251